On May 8, 2025, analyst Ami Fadia from Needham reiterated a "Buy" rating for Avadel Pharmaceuticals (AVDL, Financial). The price target for AVDL remains unchanged at $19.00 USD, maintaining the previous target set by the analyst.
This reaffirmation from Needham indicates steady confidence in Avadel Pharmaceuticals' market performance and future prospects. Investors should note that the price target has not seen any percentage change, remaining consistent with prior analysis.
Avadel Pharmaceuticals (AVDL, Financial) continues to be a focus of Needham's positive outlook, as reflected by the maintained "Buy" rating and stable price target of $19.00 USD.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Avadel Pharmaceuticals PLC (AVDL, Financial) is $17.80 with a high estimate of $22.00 and a low estimate of $12.00. The average target implies an upside of 87.96% from the current price of $9.47. More detailed estimate data can be found on the Avadel Pharmaceuticals PLC (AVDL) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Avadel Pharmaceuticals PLC's (AVDL, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
